Seeking Alpha

Merck updates investors

  • Notable points conveyed by Merck (MRK) CEO Ken Frazier in his investor presentation: Consumer business sales to Bayer (BAYRY) was 7x sales, expected to close in 2H; CV collaboration: Adempas (riociguat) lauched in U.S., E.U. and Japan, Variciguat (BAY 102) in Phase 2 trial, $1B upfront payment to Bayer.
  • Cancer immunotherapy candidate MK-3475 BLA filed, granted priority review.
  • Nine Phase 3 trials underway; ten near-term new product launches possible; ten markets deliver 70% of MRK revenue; top 50 customers expected to deliver 50% of revenue by 2016.
  • Grow EPS off the 2014 base; deliver industry-leading ROC to shareholders.
From other sites
Comments (2)
  • ericskey
    , contributor
    Comment (1) | Send Message
     
    " ten markets deliver 70% of MRK revenue; top 50 customers expected to deliver 50% of revenue by 2016."

     

    This sounds a lot like all of one's eggs in one basket.
    6 May 2014, 10:26 AM Reply Like
  • biochemist
    , contributor
    Comments (527) | Send Message
     
    That is the reality for all the big pharmas. Before MRK's merger with SGP 70% of revenue came from the US alone.
    6 May 2014, 05:35 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs